PLoS ONE (Jan 2021)

Natural autoantibodies to the gonadotropin-releasing hormone receptor in polycystic ovarian syndrome.

  • Lisa-Marie Sattler,
  • Hanna A Schniewind,
  • Waldemar B Minich,
  • Christoph W Haudum,
  • Petra Niklowitz,
  • Julia Münzker,
  • Gábor L Kovács,
  • Thomas Reinehr,
  • Barbara Obermayer-Pietsch,
  • Lutz Schomburg

DOI
https://doi.org/10.1371/journal.pone.0249639
Journal volume & issue
Vol. 16, no. 4
p. e0249639

Abstract

Read online

ContextPolycystic ovarian syndrome (PCOS) is a complex disease with different subtypes and unclear etiology. Among the frequent comorbidities are autoimmune diseases, suggesting that autoantibodies (aAb) may be involved in PCOS pathogenesis.ObjectiveAs the gonadal axis often is dysregulated, we tested the hypothesis that aAb to the gonadotropin-releasing hormone receptor (GnRH-R) are of diagnostic value in PCOS.DesignAn in vitro assay for quantifying aAb to the GnRH-R (GnRH-R-aAb) was established by using a recombinant fusion protein of full-length human GnRH-R and firefly luciferase. A commercial rabbit antiserum to human GnRH-R was used for standardization. Serum samples of control subjects and different cohorts of European PCOS patients (n = 1051) were analyzed.ResultsThe novel GnRH-R-aAb assay was sensitive, and signals were linear on dilution when tested with the commercial GnRH-R antiserum. Natural GnRH-R-aAb were detected in one control (0.25%) and two PCOS samples (0.31%), and 12 samples were slightly above the threshold of positivity. The identification of samples with positive GnRH-R-aAb was reproducible and the signals showed no matrix interferences.ConclusionNatural GnRH-R-aAb are present in a very small fraction of adult control and PCOS subjects of European decent. Our results do not support the hypothesis that the GnRH-R constitutes a relevant autoantigen in PCOS.